Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts

New blood vessel formation within tumours is a critical feature for tumour growth. A major limitation in understanding this complex process has been the inability to visualise and analyse vessel formation. Here, we report on the development of a whole-tissue mount technique that allows visualisation of vessel structure. Mice expressing green fluorescent protein (GFP) made it possible to easily see GFP+ vessels within non-GFP-expressing B16 melanoma tumours. The small fragments of tumour used in this technique were also effectively stained with fluorescent probe-conjugated antibodies, allowing characterisation of the vessels based on surface marker phenotype. The vessels within tumour tissue were much more irregular and tortuous compared to those within surrounding normal muscle. B16 tumours stably transfected with the genes for IL-12 were used to assess the effects of this cytokine on tumour growth and vessel formation. The IL-12-expressing tumours grew more slowly and had much smaller blood vessels than the large, webbed vessels characteristic of the parental tumours, effects that were dependent on interferon gamma (IFN-γ). Vessels in the parental tumours were found to express VEGFR-3, the receptor for VEGF-C and VEGF-D. Expression of this receptor by the endothelial cells of the blood vessels was lost in the cytokine expressing tumours, thus suggesting a mechanism for the antiangiogenic effects of IL-12. The combination of the whole mount technique and the GFP transgenic mice provides a powerful method for visualising tumour vasculature and characterising the effects of agents such as cytokines.

[1]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[2]  S. Fuggle,et al.  THE DETAILED DISTRIBUTION OF HLA‐A, B, C ANTIGENS IN NORMAL HUMAN ORGANS , 1984, Transplantation.

[3]  J. Folkman,et al.  Tumoral vascularity as a prognostic factor in cancer. , 1996, Important advances in oncology.

[4]  G. Trinchieri,et al.  B7-1 and interleukin 12 synergistically induce effective antitumor immunity. , 1995, Cancer research.

[5]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[6]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[7]  M. Serio,et al.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.

[8]  M. Karkkainen,et al.  Vascular endothelial growth factor receptor-3. , 1999, Current topics in microbiology and immunology.

[9]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[10]  E. Berg,et al.  Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[11]  P. Vaupel,et al.  Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts , 2001, International Journal of Gynecologic Cancer.

[12]  B. Car,et al.  The Toxicology of Interleukin-12: A Review , 1999, Toxicologic pathology.

[13]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[14]  S. Stacker,et al.  Localization of vascular endothelial growth factor‐D in malignant melanoma suggests a role in tumour angiogenesis , 2001, The Journal of pathology.

[15]  M. Colombo,et al.  IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk1 , 2001, The Journal of Immunology.

[16]  G. Trinchieri,et al.  Interleukin-12: basic principles and clinical applications. , 1999, Current topics in microbiology and immunology.

[17]  P. Lollini,et al.  Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. , 1998, Cancer research.

[18]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[19]  C. Orosz,et al.  Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. , 1989, Transplantation.

[20]  N. J. McNally,et al.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.

[21]  A. Chang,et al.  Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. , 1996, Cancer research.

[22]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[23]  D. Ruiter,et al.  Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. , 2002, Cancer research.

[24]  K. Alitalo,et al.  VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  G. Trinchieri,et al.  The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. , 1997, Cancer research.

[26]  G. Trinchieri Interleukin-12: a cytokine at the interface of inflammation and immunity. , 1998, Advances in immunology.

[27]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[28]  T. Veikkola,et al.  VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.

[29]  N. Yang,et al.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[31]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Tisch,et al.  Distribution and characterization of GFP(+) donor hematogenous cells in Twitcher mice after bone marrow transplantation. , 2000, The American journal of pathology.

[33]  K. Sullivan,et al.  Green Fluorescent Proteins , 1999 .

[34]  A. McAdam,et al.  Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. , 1995, Cellular immunology.

[35]  P. Vaupel Hypoxia in neoplastic tissue. , 1977, Microvascular research.

[36]  J. Folkman Tumor angiogenesis in women with node-positive breast cancer. , 1995, The cancer journal from Scientific American.

[37]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[38]  P. Hewett,et al.  Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. , 2002, Cancer research.

[39]  D. Brewster,et al.  Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.

[40]  F. Balkwill,et al.  IL‐12 regulates VEGF and MMPs in a murine breast cancer model , 1998, International journal of cancer.